585 related articles for article (PubMed ID: 30623408)
1. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
[TBL] [Abstract][Full Text] [Related]
2. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD).
Park CW; Kim BJ; Lee YW; Won C; Park CO; Chung BY; Lee DH; Jung K; Nam HJ; Choi G; Park YH; Kim KH; Park M
J Allergy Clin Immunol; 2022 Apr; 149(4):1340-1347.e4. PubMed ID: 34606832
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
[TBL] [Abstract][Full Text] [Related]
5. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
Lim KM; Park YH
Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis.
Draelos ZD; Traub M; Gold MH; Green LJ; Amster M; Barak-Shinar D; Kircik LH
J Drugs Dermatol; 2019 Oct; 18(10):1038-1045. PubMed ID: 31584783
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the histamine H
Werfel T; Layton G; Yeadon M; Whitlock L; Osterloh I; Jimenez P; Liu W; Lynch V; Asher A; Tsianakas A; Purkins L
J Allergy Clin Immunol; 2019 May; 143(5):1830-1837.e4. PubMed ID: 30414855
[TBL] [Abstract][Full Text] [Related]
9. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
[TBL] [Abstract][Full Text] [Related]
10. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
11. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
[TBL] [Abstract][Full Text] [Related]
12. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial.
Marini A; Reinelt K; Krutmann J; Bilstein A
Skin Pharmacol Physiol; 2014; 27(2):57-65. PubMed ID: 23949258
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
14. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
16. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
20. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
